NEW YORK (TheStreet) -- DARA BioSciences (DARA) surged Monday after the company announced the FDA had granted Orphan Drug Designation to the company's experimental compound KRN5500 for the treatment of multiple myeloma.
The stock was up 26.74% to $1.42 at 10:50 a.m. More than 15.2 million shares had changed hands, which eclipsed the average volume of 748,475.
Must Read: Warren Buffett's 25 Favorite Stocks
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts